Zobrazeno 1 - 10
of 56
pro vyhledávání: '"Hubert van Hoogstraten"'
Autor:
Jeffrey R. Curtis, Huifeng Yun, Lang Chen, Stephanie S. Ford, Hubert van Hoogstraten, Stefano Fiore, Kerri Ford, Amy Praestgaard, Markus Rehberg, Ernest Choy
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 4, Pp 1055-1072 (2023)
Abstract Introduction Clinical trial findings may not be generalizable to routine practice. This study evaluated sarilumab effectiveness in patients with rheumatoid arthritis (RA) and tested the real-world applicability of a response prediction rule,
Externí odkaz:
https://doaj.org/article/80bfab0a874e486da7941d72c601d787
Autor:
Thomas Huizinga, Ernest Choy, Amy Praestgaard, Hubert van Hoogstraten, Patrick R. LaFontaine, Patricia Guyot, Daniel Aletaha, Ulf Müller-Ladner, Yoshiya Tanaka, Jeffrey R. Curtis, Roy Fleischmann
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 3, Pp 539-550 (2023)
Abstract Introduction The efficacy of sarilumab and upadacitinib, in combination with disease-modifying antirheumatic drugs (DMARDs), was demonstrated in phase 3 clinical trials of patients with rheumatoid arthritis (RA) refractive to previous biolog
Externí odkaz:
https://doaj.org/article/d705218c26a84ae980d82074b13580e4
Autor:
Jeffrey R. Curtis, Huifeng Yun, Lang Chen, Stephanie S. Ford, Hubert van Hoogstraten, Stefano Fiore, Kerri Ford, Amy Praestgaard, Markus Rehberg, Ernest Choy
Publikováno v:
Rheumatology and Therapy, Vol 11, Iss 1, Pp 217-217 (2023)
Externí odkaz:
https://doaj.org/article/05ceb80625a94892a3e20045335a876e
Autor:
Mark C. Genovese, Roy Fleischmann, Alan Kivitz, Eun-Bong Lee, Hubert van Hoogstraten, Toshio Kimura, Gregory St John, Erin K. Mangan, Gerd R. Burmester
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-17 (2020)
Abstract Background The interleukin-6 receptor inhibitor sarilumab demonstrated efficacy in combination with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or as monotherapy in patients with moderately to severely active rheu
Externí odkaz:
https://doaj.org/article/12ab6b3c9513426f81af28505c83a39c
Autor:
Cem Gabay, Gerd R. Burmester, Vibeke Strand, Jérôme Msihid, Moshe Zilberstein, Toshio Kimura, Hubert van Hoogstraten, Susan H. Boklage, Jonathan Sadeh, Neil M. H. Graham, Anita Boyapati
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background Interleukin-6 (IL-6) is a pleiotropic cytokine that plays a key role in the pathogenesis of rheumatoid arthritis. Sarilumab is a human monoclonal antibody that binds membrane-bound and soluble IL-6 receptor-α to inhibit IL-6 sign
Externí odkaz:
https://doaj.org/article/9f7d47705237485b86eba702a5fcce61
Autor:
Alvin F. Wells, Janie Parrino, Erin K. Mangan, Anne Paccaly, Yong Lin, Christine Xu, Chunpeng Fan, Neil M. H. Graham, Hubert van Hoogstraten, Albert Torri
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 3, Pp 339-352 (2019)
Abstract Introduction This open-label study evaluated the immunogenicity, safety, and efficacy of sarilumab monotherapy in patients with active, moderate-to-severe rheumatoid arthritis (RA) and inadequate response or intolerance to prior conventional
Externí odkaz:
https://doaj.org/article/c4ff01ffaea0496db79cb29f61362bca
Autor:
Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham, Hideto Kameda
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-14 (2019)
Abstract Background Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor α. This bridging study assessed the efficacy and safety of sa
Externí odkaz:
https://doaj.org/article/c4d5566649434cd293bbb55ae6b1b2d3
Autor:
Vibeke Strand, Laure Gossec, Clare W. J. Proudfoot, Chieh-I Chen, Matthew Reaney, Sophie Guillonneau, Toshio Kimura, Janet van Adelsberg, Yong Lin, Erin K. Mangan, Hubert van Hoogstraten, Gerd R. Burmester
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-12 (2018)
Abstract Background The phase III MONARCH randomized controlled trial (NCT02332590) demonstrated that in patients with rheumatoid arthritis (RA), sarilumab (anti-interleukin-6 receptor monoclonal antibody) monotherapy is superior to adalimumab monoth
Externí odkaz:
https://doaj.org/article/0f4f3986999d4d779a961f01dcdc58ab
Autor:
Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham, Hideto Kameda
Publikováno v:
Arthritis Research & Therapy, Vol 21, Iss 1, Pp 1-3 (2019)
Following publication of the original article [1], the authors reported an error in Table 2.
Externí odkaz:
https://doaj.org/article/aa5b449d10c34b929839187b100615bc
Autor:
Ernest Choy, Nick Freemantle, Clare Proudfoot, Chieh-I Chen, Laurence Pollissard, Andreas Kuznik, Hubert Van Hoogstraten, Erin Mangan, Paulo Carita, Thi-Minh-Thao Huynh
Publikováno v:
RMD Open, Vol 5, Iss 1 (2019)
Objective To compare efficacy and safety of subcutaneous sarilumab 200 mg and 150 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARDs) versus other targeted DMARDs+csDMARDs and placebo+csDMARDs, in inadequate
Externí odkaz:
https://doaj.org/article/671e2ff010a240f081695b7e00af6da0